Literature DB >> 1373758

Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope.

T C Rodman1, F H Pruslin, S E To, R Winston.   

Abstract

We have detected, in sera of normal human immunodeficiency virus (HIV)-free subjects, IgM antibodies reactive with the Tat protein of HIV in significant titers and at very high frequency, and, in HIV-positive sera, progressively lower titers as HIV pathogenesis ensues. Epitope analysis indicates that the Tat-reactive antibodies of both HIV-negative and HIV-positive sera are homologous, suggesting, therefore, that their decline in HIV-positive sera may represent attrition of a host defense factor. The identified epitope displays minimal homology with that previously defined for another set of IgM antibodies shown to be present in normal sera, deficient in HIV-positive sera, and postulated to be natural antibodies. We propose that the Tat-reactive antibodies, as well, are a set of natural antibodies and that the normal humoral immune system includes a repertoire of antibodies, nonimmunogenic in origin, that contribute to immune homeostasis and, consequently, to host resistance to HIV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373758      PMCID: PMC2119208          DOI: 10.1084/jem.175.5.1247

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Caveats and suggestions for the ELISA.

Authors:  F H Pruslin; S E To; R Winston; T C Rodman
Journal:  J Immunol Methods       Date:  1991-03-01       Impact factor: 2.303

2.  THE NATURAL-SELECTION THEORY OF ANTIBODY FORMATION.

Authors:  N K Jerne
Journal:  Proc Natl Acad Sci U S A       Date:  1955-11-15       Impact factor: 11.205

3.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

Review 4.  CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire.

Authors:  P Casali; A L Notkins
Journal:  Immunol Today       Date:  1989-11

5.  Survival analysis of hemophilia-associated AIDS cases in the US.

Authors:  J K Stehr-Green; R C Holman; M A Mahoney
Journal:  Am J Public Health       Date:  1989-07       Impact factor: 9.308

6.  Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.

Authors:  W J Krone; C Debouck; L G Epstein; P Heutink; R Meloen; J Goudsmit
Journal:  J Med Virol       Date:  1988-11       Impact factor: 2.327

7.  Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat.

Authors:  J Sodroski; C Rosen; F Wong-Staal; S Z Salahuddin; M Popovic; S Arya; R C Gallo; W A Haseltine
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

8.  Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat.

Authors:  D A Brake; C Debouck; G Biesecker
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

9.  Human immunodeficiency virus induction of malignant transformation in human B lymphocytes.

Authors:  J Laurence; S M Astrin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.

Authors:  P Reiss; F de Wolf; C L Kuiken; A de Ronde; J Dekker; C A Boucher; C Debouck; J M Lange; J Goudsmit
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991
View more
  7 in total

1.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

Authors:  S S Cohen; C Li; L Ding; Y Cao; A B Pardee; E M Shevach; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Authors:  Valentina Finessi; Francesco Nicoli; Eleonora Gallerani; Fabio Sforza; Mariaconcetta Sicurella; Aurelio Cafaro; Antonella Caputo; Barbara Ensoli; Riccardo Gavioli
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.

Authors:  Elisabetta Caselli; Michela Boni; Arianna Bracci; Antonella Rotola; Claudio Cermelli; Massimiliano Castellazzi; Dario Di Luca; Enzo Cassai
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.

Authors:  T C Rodman; S E To; H Hashish; K Manchester
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

Review 5.  Role of Tat protein in HIV neuropathogenesis.

Authors:  Wenxue Li; Guanhan Li; Joseph Steiner; Avindra Nath
Journal:  Neurotox Res       Date:  2009-03-21       Impact factor: 3.911

6.  Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein.

Authors:  Nagadenahalli Byrareddy Siddappa; Mohanram Venkatramanan; Prasanna Venkatesh; Mohanbabu Vijayamma Janki; Narayana Jayasuryan; Anita Desai; Vasanthapuram Ravi; Udaykumar Ranga
Journal:  Retrovirology       Date:  2006-08-18       Impact factor: 4.602

7.  Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.

Authors:  Francesco Nicoli; Mkunde Chachage; Petra Clowes; Asli Bauer; Dickens Kowour; Barbara Ensoli; Aurelio Cafaro; Leonard Maboko; Michael Hoelscher; Riccardo Gavioli; Elmar Saathoff; Christof Geldmacher
Journal:  BMC Infect Dis       Date:  2016-07-22       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.